There is increasing evidence to support a role for mitochondrial damage and dysfunction in aging and chronic neurodegenerative disorders, including age-related macular degeneration (AMD).
1,2 Studies on the aging retina have reported significant age-related decreases in the number and size of mitochondrial in human RPE cells,
3 accumulation of mitochondrial DNA deletions,
4 and increased mitochondrial DNA damage and downregulation of DNA repair enzymes in aged rodent neural retina and RPE/choroid.
5,6 The potential consequences of these detrimental mitochondrial changes include increased generation of reactive oxygen species and decreased metabolic activity, which impede the cells' optimal bioenergetics.
1 It is only within the past decade that the potential role for mitochondrial damage and dysfunction in AMD has been realized. mtDNA haplotypes have been identified that are associated with either increased or decreased prevalence of AMD,
7 and persons with AMD have high levels of large mtDNA deletions/rearrangements in the retina, unreported and amino acid-changing SNPs in the coding genome, and more SNPs per person in the noncoding MT-Dloop region.
8 Studies have focused largely on the RPE given its critical role in photoreceptor maintenance, its atrophy in dry AMD, and the view that the RPE is the site of the primary defect in AMD. Karunadharma et al.
9 recently reported that with aging mtDNA damage was observed only in the common deletion region of the mitochondrial genome, whereas, in contrast, with AMD the mtDNA lesions increased significantly in all regions of the mitochondrial genome beyond levels found in age-matched controls. These changes are also associated with a significant decrease in the number and area of mitochondria and the loss of cristae and matrix density in AMD compared with age-matched controls
3 and alterations in proteins associated with mitochondrial translation, import of nuclear-encoded proteins, and adenosine triphosphate synthase activity in RPE from AMD patients.
10